Deploying next-generation adjuvants to enhance protection of a group A streptococcal vaccine candidate

使用下一代佐剂来增强对 A 组链球菌候选疫苗的保护

• 批准号: nhmrc : GNT1153718
• 负责人: Dr Nicole Moreland
• 金额: $ 105.23万
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/deploying-next-generation-vaccine-candidate/1349118
• 关键词: Deploying; next; generation; adjuvants; enhance

Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified new protective candidate antigens, and we seek to undertake critical non-human primate studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (GSK) leading to human trials and the development of a safe group A streptococcal vaccine for human use.

A组链球菌每年导致52万人死亡。目前还没有一种安全有效的疫苗可供商业使用。我们已经确定了新的保护性候选抗原，我们寻求进行关键的非人灵长类动物研究，以提供进一步的概念验证数据。这项工作将支持我们的行业合作伙伴（GSK）的商业决策，从而导致人体试验和开发安全的A组链球菌疫苗供人类使用。